)
Visual
test
Diaceutics
Diaceutics (DXRX) investor relations material
Diaceutics Q4 2025 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 TU earnings summary15 Jan, 2026
Executive summary
Reported revenues expected at £38.5 million for FY 2025, a 20% increase year-over-year, with a return to profitability and strong commercial momentum.
Constant currency revenue growth projected at 24%, aligning with analyst consensus.
Record order book of at least £36.8 million and ARR exceeding £20.3 million, reflecting robust recurring revenue growth.
Expanded customer base, with 12% growth in therapeutic brands to 95 and three new enterprise-wide customers added.
Second PMx commercialisation partnership signed, supporting further commercial growth.
Financial highlights
Adjusted EBITDA expected to surpass analyst consensus, with approximately 75% year-over-year growth and a margin of about 19%.
Profit after tax achieved, marking a return to profitability.
Annual Recurring Revenue (ARR) up 21% to over £20.3 million, with USD ARR growth exceeding 30%.
Order book up 48% year-over-year to at least £36.8 million.
Ten enterprise-wide engagements live across 36 brands, generating £13.0 million in ARR.
Outlook and guidance
25% revenue growth expected for FY 2026.
Continued acceleration in precision medicine adoption among pharma and biotech customers.
Ongoing enhancements to the DXRX platform driving operational leverage and expanded revenue opportunities.
How does agentic AI drive operating leverage?
What new therapeutic areas are targeted beyond PMx?
What's the ARR contribution per enterprise engagement?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Diaceutics
- AI-powered DXRX platform drives high-margin recurring revenue and ROI in precision medicine.DXRX
CME 20241 Feb 2026 - 24% revenue growth, 55% recurring revenue, and PMx launch set stage for 2025 profitability.DXRXH1 202420 Jan 2026
- 39% revenue growth, 88% margin, and US expansion drive 2025 profitability shift.DXRXH2 202418 Nov 2025
- Revenue up 22% to £14.6m, ARR up 16%, and positive EBITDA signal profitability on track.DXRXH1 202523 Sep 2025
- 22% revenue growth, rising recurring revenues, and strong pipeline underpin FY 2025 confidence.DXRXTrading Update22 Jul 2025
- Revenue up 24% in H1 2024, with 55% recurring and strong growth in enterprise engagements.DXRXTrading Update13 Jun 2025
- Diaceutics delivered 39% revenue growth and strong ARR gains, supporting robust 2025 outlook.DXRXTrading Update6 Jun 2025
Next Diaceutics earnings date
H2 202512 May, 2026
Diaceutics
Next Diaceutics earnings date
H2 202512 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage